Findings assess the functional contribution of Angiopoietin family members to tumor angiogenesis and suggest that it is their relative ratio that guides vascular growth.
Introduction
The transition from pre-vascular hyperplasia to highly vascularized, outgrowing tumors is referred to as the "angiogenic switch" (1) . The requirement of active angiogenesis for tumor outgrowth has been repeatedly demonstrated, for example by depletion of angiogenic growth factors or by the specific targeting of the activities of their receptors (2) (3) (4) . Many factors are involved in inducing tumor angiogenesis and, among them, members of the Vascular Endothelial Growth Factor (VEGF) family, Fibroblast Growth Factors (FGFs), and several others have been extensively studied (2) (3) (4) . By binding to their cognate receptor Tie-2, angiopoietins (Ang) have also been shown to exert critical roles during physiological angiogenesis and tumor angiogenesis. The family includes four ligands (Ang-1 to 4) and two corresponding tyrosine kinase receptors (Tie-1 and Tie-2) (5,6). While Ang-3 and 4, diverging gene counterparts of mice and human, respectively, are still poorly understood, Ang-1 and Ang-2 have been intensely studied. Both specifically bind Tie-2 receptor with comparable affinities (7) . However, while Ang-1 is an agonist of Tie-2 receptor signaling, in most circumstances Ang-2 exerts an antagonistic function. Ang-1 is predominantly expressed by mesenchymal cells and acts in a paracrine manner by binding Tie-2 receptors expressed on endothelial cells. Ang-1-mediated Tie-2 activation promotes vessel assembly and maturation by mediating survival signals for endothelial cells and by stimulating the recruitment of mural cells (8) . Ang-1-mediated vessel stabilization can be seen as vessel normalization (9) .
In contrast, Ang-2 is mainly produced by endothelial cells and stored in Weibel-Palade bodies from where it is released by activating cues and acts as an autocrine antagonist of Ang-1-mediated Tie-2 activation (6,10). Ang-2 thereby primes and activates vascular endothelium to respond to other angiogenic factors, such as VEGF, and induces vascular destabilization but also vascular sprouting and branching. However, Ang-2 has also been reported to activate Tie-2 signaling, yet the molecular basis for its dual function is not fully understood (11, 12) . 
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expression of Ang-2 in different tumor cell lines has also resulted in varying outcomes: it either enhanced the growth of hypervascular, often more invasive tumors (13) (14) (15) (16) or it suppressed tumor growth by disrupting adequate tumor angiogenesis and vessel maturation (17) . On the other hand, tumor growth is impaired in Ang-2-deficient mice (18) .
The roles of Ang-1 and Ang-2 in tumor angiogenesis and tumor outgrowth have not been directly compared in stochastically growing tumors. Here, we have employed the Rip1Tag2 transgenic mouse model of pancreatic β-cell carcinogenesis to force the expression of Ang-1 and Ang-2 during multistage tumor development. In Rip1Tag2 transgenic mice, SV40 large T antigen (Tag) is expressed under the control of the rat insulin promoter (Rip1) specifically in the insulin-producing β-cells of pancreatic islets of Langerhans (19) . Several tumor stages can be distinguished, including β-cell hyperplasia, angiogenic dysplasia, adenoma, and carcinoma (20,21).
One of the factors inducing angiogenesis in tumors of Rip1Tag2 mice is VEGF-A. It is secreted by β-tumor cells, and matrix-associated VEGF-A is released by matrix metalloproteinase-9 (MMP-9) concomitantly with the onset of angiogenesis (22) .
Consistent with these findings, inhibition of VEGF-A or MMP function represses tumor angiogenesis (23) (24) (25) .
To assess the functional contribution of Ang-1 and Ang-2 to tumor angiogenesis, we have generated transgenic mouse lines, where either human Ang-1 (hAng-1) or human Ang-2 (hAng-2) are expressed under the control of the Rip1 promoter (Rip1Ang-1 or Rip1Ang-2). Rip1Ang-1 or Rip1Ang-2 mice were then crossed with Rip1Tag2 mice. Transgenic expression of both Ang-1 and Ang-2 led to the formation of lymphatic vessels around islets of Langerhans and β-cell tumors.
While Ang-1 only marginally increased blood vessel maturation and tumor growth, the expression of Ang-2 led to increased numbers of infiltrating leukocytes, elevated levels of VEGF-A expression, aberrant tumor angiogenesis and, with it, retarded 
Material and Methods

Mice
The generation of Rip1Ang-1 and Rip1Ang-2 single-transgenic mice and of Rip1Tag2;Rip1Ang-1 and Rip1Tag2;Rip1Ang-2 double-transgenic mice is described in Supplemental Material. Rip1Tag2;Rip1Ang-1 and Rip1Tag2;Rip1Ang-2 and Rip1Tag2 littermate control mice were sacrificed between 12 and 13 weeks of age.
PTK787/ZK222584 (PTK/ZK) was kindly provided by Novartis Pharma, Basel, Switzerland. 12 weeks old Rip1Tag2 or Rip1Tag2;Rip1Ang-2 mice were treated with either 100 mg/kg bodyweight PTK/ZK dissolved in polyethylene glycol 300 (PEG-300; Sigma-Aldrich) or PEG-300 alone by daily oral administration for 5 days. All experimental procedures involving mice were performed according to the guidelines of the Swiss Federal Veterinary Office (SFVO) and the regulations of the Cantonal Veterinary Office of Basel Stadt.
Histopathological analysis
Processing of tissues for histological analysis is described in Supplemental Material.
Histologic analysis and immunostaining was done on paraffin sections (5 μm) or on cryosections (7 μm) as previously described (26, 27) . For three-dimensional confocal reconstruction images, pancreatic cryosections (80-100 μm) were used (28). 
Lectin perfusion
For the analysis of functional blood vessels, mice were tail vein-injected with 100 μl of 1 mg/ml fluorescein-labeled Lycopersicon esculentum lectin (FL-1171, Vector Laboratories, Buringame, CA, USA) under i.p. anesthesy with Nembutal Sodium Solution (Abbott Laboratories, North Chicago, IL, USA). After 5 min, mice were heart perfused with 10 ml of 4% PFA followed by 10 ml PBS. Isolated pancreata were immersed in ascending concentrations of sucrose (12%, 15%, and 18% for 1 h each at +4°C) overnight and embedded in OCT.
Cell lines
Human Umbilical Vein Endothelial Cells (HUVEC) were purchased from ATCC (Washington, DC, USA) and used at low passage numbers and without further authentication for the collagen gel assay described in Suppl. Methods.
Statistical analyses
Statistical analysis was performed using GraphPad Prism software (GraphPad Software Inc., San Diego, USA).
Results
Transgenic expression of human Ang-1 and Ang-2
Quantitative reverse transcription-PCR (qRT-PCR) and immunoblotting analysis revealed that endogenous mouse Ang-1 and Ang-2 were expressed at low levels in the β-cells of pancreatic islets of Langerhans or in tumors of Rip1Tag2 ends with a signal peptide and a 10-amino acid Myc-tag were cloned between the rat insulin II gene promoter fragment Rip1 (19) and a SV40 polyadenylation site (27) (Suppl. Figure 2B ). Seven Rip1Ang-1 and six Rip1Ang-2 founder lines were analyzed for transgene expression by RT-PCR, immunoblotting and immunofluorescence microscopy using specific antibodies against human angiopoietins and against myc- non-transgenic controls (Figure 2A , B). These results indicate that both Ang-1 and Ang-2 are able to induce lymphangiogenesis, an observation consistent with previous reports that mice deficient in Ang-2 expression exhibit defects in lymphangiogenesis and that Ang-1 is capable of inducing lymphatic sprouting and hyperplasia (29-31).
Ang-1 and Ang-2 affect tumor growth
To assess the role of Ang-1 and Ang-2 in tumorigenesis, RA-1 and RA-2 transgenic mice were crossed with Rip1Tag2 (RT2) mice. The resulting RT2 singletransgenic mice and Rip1Tag2;Rip1Ang-1 (RTRA-1) or Rip1Tag2;Rip1Ang-2 (RTRA-2) double-transgenic mice were sacrificed between 12 and 13 weeks of age, when these mice succumb to hypoglycemia caused by excessive tumoral insulin production. Immunofluorescence and immmunoblotting analysis revealed that in RTRA-1 and RTRA-2 double-transgenic mice most β-tumor cells expressed human Ang-1 and Ang-2, respectively (Suppl. Figures 2B, 5, 6 ), yet human or mouse angiopoietins were not detectable by ELISA in the serum of these mice (data not shown).
Tumor growth in RTRA-1 mice was moderately, yet not significantly increased as compared to single-transgenic RT2 littermates ( Figure 3A ). Histological analysis of tumor progression revealed that the numbers of normal and hyperplastic islets, adenomas and carcinomas were unchanged ( Figure 3A) . In contrast, RTRA-2 mice displayed a significant reduction in tumor volumes ( Figure 3B ) and in the numbers of tumors per mouse (3.64 ± 0.33 for RTRA-2 vs. 5.48 ± 0.35 for RT2). Furthermore, the fraction of hyperplastic islets and adenomas increased, whereas carcinomas were decreased in RTRA-2 mice ( Figure 3B ). Stainings with antibodies against insulin on histological sections of pancreas, liver and lung did not reveal any metastasis in lymph nodes and lung (Suppl. Figure 7A ), while micrometastasis detectable in the livers of these mice was not affected by the transgenic expression of Ang-1 and Ang-2, respectively (Suppl. Figure 7B ). Concomitant with the increased and reduced tumor growth in RTRA-1 and in RTRA-2 mice, respectively, the numbers of proliferating, phosphohistone-3-positive β-tumor cells were significantly increased in RTRA-1 and significantly decreased in RTRA-2 mice ( Figure 3A, B) . In addition, analysis of apoptosis by staining for cleaved caspase-3 revealed a significant reduction in the number of apoptotic cells within the tumors of RTRA-1 and a significant increase in RTRA-2 mice ( Figure 3A, B) .
Aberrant tumor angiogenesis in RTRA-2 mice
The slight increase and the significant decrease of tumor outgrowth in RTRA- 
interactions in RTRA-2 mice ( Figure 5B ).
To investigate whether Ang-1 or Ang-2 exerted a direct pro-angiogenic function, we co-cultured isolated dysplastic islets in a collagen matrix together with human umbilical vein endothelial cells (HUVEC). In this assay, angiogenic dysplastic islets derived from RT2 mice induce HUVEC migration, proliferation and tube formation, whereas non-angiogenic islets fail to do so (21, 27) . In this assay, islets from 9 weeks old RT2, RTRA-1 and RTRA-2 mice did not show any significant difference in their angiogenic activities (Suppl. Figure 8A- Figure 9A ). To examine whether Ang-1 or Ang-2 were able to activate Tie-2, proteins phosphorylated on tyrosine residues were immunoprecipitated from tumors of RT2, RTRA-1 and RTRA-2 mice and phosphorylated Tie-2 was then detected by immunoblotting with antibodies against Tie-2 (Suppl. Figure 9B ). Phosphorylated Tie-2 was found at comparable levels between the three genotype mice. This result was further confirmed by ELISA determining the levels of phospho-Tie-2 (Suppl. Figure   9C ) and by immunofluorescence analysis with an antibody specifically recognizing phospho-Tie-2 (Suppl. Figure 10) . Together, these analyses revealed that the transgenic expression of Ang-1 and Ang-2 did not significantly change the overall levels of Tie-2 receptor activation.
Previously, it has been reported that Ang-2 and VEGF-A act together to induce angiogenesis. In fact, Ang-2 by itself induces vessel regression in the absence of VEGF-A or upon inhibition of VEGF-A (32). To address whether Ang-2 cooperates with VEGF-A in modulating tumor angiogenesis in RTRA-2 mice we determined VEGF-A mRNA and protein levels in tumors and serum of the various genotype mice (Suppl. Figure 11A, B) . Indeed, VEGF-A levels were significantly 
higher in RTRA-2 mice and lower in RTRA-1 mice as compared to RT2 control mice.
To test the possibility that in RTRA-2 double-transgenic mice, VEGF-A and Ang-2 work synergistically to promote tumor angiogenesis, the small-molecule VEGF receptor inhibitor PTK787/ZK222584 (PTK/ZK; 33) was used to interfere with VEGF receptor function in RTRA-2 mice. PTK/ZK has been previously reported to efficiently repress tumor angiogenesis and tumor growth in the RT2 mouse model (24) . Tumor growth and tumor angiogenesis were significantly repressed after treatment of 12 week-old RT2 and RTRA-2 mice with PTK/ZK for 5 days as compared to controltreated mice (Suppl. Figure 12A-C) . Notably, the increased endothelial cell numbers in tumors of RTRA-2 mice were substantially reduced upon PTK/ZK treatment to the levels found in RT2 tumors treated with PTK/ZK. This result indicates that the Ang-2-mediated increase in endothelial cell density, as observed in RTRA-2 mice, relies on VEGF-A function. However, the cooperation between Ang-2 and VEGF-A leads to the generation of many non-functional vessels.
Inflammatory cell infiltration in tumors of RTRA-1 and RTRA-2 mice
VEGF-A is known to recruit bone marrow-derived cells to sites of active angiogenesis (34, 35) . In particular, monocytes/macrophages are well known to contribute to tumor progression and tumor-associated angiogenesis (2,36,37).
Immunofluorescence staining revealed that the numbers of tumor-infiltrating F4/80+ macrophages and of 7/4+ neutrophils were significantly reduced in RTRA-1 tumors and significantly increased in RTRA-2 tumors (Figure 6A-D) , while the overall numbers of CD45-positive inflammatory cells did not differ between tumors of RT2, RTRA-1 and RTRA-2 mice (Figure 6C, D) . However, neither Ang-2 nor Ang-1 were able to affect the infiltration of macrophages or neutrophils into islets of RA-1 and RA-2 mice as compared to C57Bl/6 mice (Suppl. Figure 13 ). 
Ang-1 and Ang-2-mediated tumor lymphangiogenesis
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We next determined the lymphatic vessel densities in tumors of RTRA-1 and RTRA-2 double-transgenic mice by LYVE-1 immunofluorescence staining. In agreement with previous reports, tumors of single-transgenic RT2 mice rarely exhibited peri-tumoral lymphatics (38, 39) . In contrast, tumors of RTRA-1 and of RTRA-2 double-transgenic mice were partially surrounded by lymphatic vessels (Figure 7A, B) . The extent of peri-tumoral lymphangiogenesis was quantified by determining the extent by which the tumor perimeters were associated with LYVE-1-positive lymphatic vessels ( Figure 7C ). The results indicate that both Ang-1 and Ang-2 are able to stimulate peri-tumoral and, more infrequently, intra-tumoral lymphangiogenesis. However, in contrast to the transgenic expression of VEGF-C and VEGF-D in RT2 mice (39, 40) , the increased lymphangiogenesis in RTRA-1 and in RTRA-2 mice did not result in metastasis to local lymph nodes or to distant organs (Suppl. Figure 7) .
Discussion
We have investigated the effects of transgenic expression of human Ang-1 or human Ang-2 in pancreatic β-cells during islet development in RA-1 or RA-2 mice and during β-cell carcinogenesis in double-transgenic RTRA-1 or RTRA-2 mice.
Expression of either Ang-1 or Ang-2 has no measurable effect on islet morphology and physiology. In double-transgenic RTRA-1 mice, the transgenic expression of Ang-1 in β-tumor cells exerts only marginal effects on angiogenesis and tumor outgrowth: similar to RT2 controls, the vessels are mature and well perfused, and only tumor cell proliferation is increased as compared to RT2 controls. In RT2, 
